Company Overview and News
14h investorplace - 1
Trying to forecast the market — and the world — a decade or two out is no easy task. That makes it difficult to choose long-term stocks to pass along to coming generations. When you’re looking for stocks to invest in for your children or grandchildren, you’re essentially looking for stocks to hold forever. So how do you go about finding such long-term stocks?
JD MCHI NFLX NVDA MDT SHLD BAC AMZN JPM IQ MKC 0700 DG NTES GM INTC DE
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney recaps morning news involving Under Armour, Nvidia, General Electric, and Red Hat. Later, he is joined by momentum guru Dave Bartosiak to discuss the Dow hitting a new all-time high and to speculate over where our major indexes might finish the year.
WFCNP UAA NVDA MS WFC GEC GE RHT UA GNE
Morgan Stanley analyst Joseph Moore wrote Thursday that "gaming data points remain mixed" for Nvidia Corp. NVDA, -1.93% amid the disappearance of the company's cryptocurrency business. "We wouldn't expect near term upside from gaming, but still like the stock," he said. Moore's note comes after tech reviewers weighed in on the company's new gaming products. "As review embargos broke for the new gaming products, performance improvements in older games is not the leap we had initially hoped for," Moore wrote.
Stocks were flat in the early morning hours on Thursday, but futures turned higher on all three major U.S. equity indexes. The markets are back to challenging their highs as well, but not necessarily in international and emerging markets. As many investors have seen lower upside from buying on market pullbacks than in prior years, they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
VIA CATR CAT AMD NVDA RHT DO ARGX TRI MS RIG BRKR
Chicago, IL – September 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Advanced Micro Devices (AMD - Free Report) , Intel (INTC - Free Report) , Cisco (CSCO - Free Report) , Hewlett Packard Enterprise (HPE - Free Report) and NVIDIA (NVDA - Free Report) .
UNP NTRS NTRSP AMD NVDA LB INTC FWRD AMWD HPE RCKY
Shares of Micron (MU - Free Report) dipped 0.60% during regular trading hours Wednesday, one day before the firm is set to release its fourth-quarter financial results. So, let’s see what investors should expect from the recently-struggling semiconductor company’s Q4 earnings results.
DB AMD NVDA
Nvidia (NVDA - Free Report) closed the most recent trading day at $271.98, moving +0.26% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.13%. Elsewhere, the Dow gained 0.61%, while the tech-heavy Nasdaq lost 0.08%.
MLHR NXTM NVDA OMN PRGS
2018-09-19 investorplace - 1
The stock market has been on an epic run. Since the 2008 Recession, the S&P 500 has gone on its longest bull run ever and has risen by more than 300% during that stretch.
HD FB SQ SHOP M NFLX GOOG NVDA CRM WMT ADBE TGT JWN AMZN GOOGL AAPL AAXN
Alphabet’s (GOOGL - Free Report) Google has struck a major deal with the largest auto alliance comprising of Renault, Nissan and Mitsubishi. Per the recent multi-year partnership, Google will deploy its Android operating system (OS) for infotainment purpose in the cars manufactured by the auto alliance. This will enable people driving the car to access Google Maps, Google Assistant, Play Store and other important apps from the car’s dashboard.
UNP GOOGL AAPL NVDA GM
With NVIDIA(NVDA), the question isn’t why they will rocket, the question is when. We say this because of the potential that it has based off of the markets that it is in. Considering the fact that the gaming market has blown up recently and is expected to keep growing in the future years, many believe that NVIDIA will run with it. Unlike other stocks with a huge market potential and high market share, NVIDIA is not overvalued.
2018-09-19 investorplace - 3
When it comes to the chip space, much of the attention has been on Advanced Micro Devices (NASDAQ:AMD) lately, whose stock has been on a powerful bull run. But of course, there are other notable operators to keep an eye on. One is Nvidia (NASDAQ:NVDA). Nvidia stock looks as if it might be back on track for growth
AMZN GOOGL AMD MSFT GOOG NVDA INTC
2018-09-19 investorplace - 2
Workers in their 30s and 40s often find themselves in tricky situations, career-wise. They’re certainly beyond their trainee days, but not yet in positions only awarded to employees with a wealth of experience and proven acumen. It’s in this time of life when workers find themselves on a clear path to some sort of senior position, or realize it’s just not going to happen.
QRVO MA PYPL AMD NVDA WMT ADBE AMZN AMT MRK GOOGL MSFT CAH INTC
2017-10-11 - Asif
Starting with a focus on PC graphics, NVIDIA invented the GPU to solve some of the most complex problems in computer science. The company has extended its emphasis in recent years to the revolutionary field of AI. NVIDIA delivers value to its customers through PC, mobile and cloud architectures. Vertical integration enables it to bring together hardware, system software, programmable algorithms, libraries, systems and services to create unique value for the markets it serve. The company specialize in markets in which GPU-based visual computing and accelerated computing platforms can provide enhanced throughput for applications. NVIDIA has two reportable segments - GPU and Tegra Processor - are based on a single underlying graphics architecture. From its proprietary processors, The company have created specialized platforms that target the four large markets where its expertise is critical: Gaming, Professional Visualization, Datacenter, and Automotive. NVIDIA's GPU product brands...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to NVDA / NVIDIA Corp. on message board site Silicon Investor.
as of ET